MA42270A - IMMUNE MODULATION AND SOLID TUMOR TREATMENT WITH ANTIBODIES BINDING SPECIFICALLY TO CD38 - Google Patents

IMMUNE MODULATION AND SOLID TUMOR TREATMENT WITH ANTIBODIES BINDING SPECIFICALLY TO CD38

Info

Publication number
MA42270A
MA42270A MA042270A MA42270A MA42270A MA 42270 A MA42270 A MA 42270A MA 042270 A MA042270 A MA 042270A MA 42270 A MA42270 A MA 42270A MA 42270 A MA42270 A MA 42270A
Authority
MA
Morocco
Prior art keywords
solid tumor
binding specifically
tumor treatment
antibodies binding
immune modulation
Prior art date
Application number
MA042270A
Other languages
French (fr)
Inventor
Tahamtan Ahmadi
Tineke Casneuf
Henk M Lokhorst
Tuna Mutis
Amy Sasser
Original Assignee
Janssen Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Biotech Inc filed Critical Janssen Biotech Inc
Publication of MA42270A publication Critical patent/MA42270A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
MA042270A 2015-06-24 2016-06-24 IMMUNE MODULATION AND SOLID TUMOR TREATMENT WITH ANTIBODIES BINDING SPECIFICALLY TO CD38 MA42270A (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562184018P 2015-06-24 2015-06-24
US201562249546P 2015-11-02 2015-11-02
US201562250566P 2015-11-04 2015-11-04
US201562263307P 2015-12-04 2015-12-04
US201662331489P 2016-05-04 2016-05-04

Publications (1)

Publication Number Publication Date
MA42270A true MA42270A (en) 2018-05-02

Family

ID=57586547

Family Applications (1)

Application Number Title Priority Date Filing Date
MA042270A MA42270A (en) 2015-06-24 2016-06-24 IMMUNE MODULATION AND SOLID TUMOR TREATMENT WITH ANTIBODIES BINDING SPECIFICALLY TO CD38

Country Status (29)

Country Link
US (1) US20160376373A1 (en)
EP (1) EP3313441B1 (en)
JP (2) JP7041519B2 (en)
KR (1) KR20180012864A (en)
CN (1) CN107921120A (en)
AU (1) AU2016281717B2 (en)
BR (1) BR112017027990A2 (en)
CA (1) CA2990620A1 (en)
CL (2) CL2017003275A1 (en)
CO (1) CO2017013332A2 (en)
DK (1) DK3313441T3 (en)
DO (1) DOP2017000305A (en)
EA (1) EA037548B1 (en)
EC (1) ECSP17084878A (en)
FI (1) FI3313441T3 (en)
GT (1) GT201700286A (en)
HK (1) HK1254942A1 (en)
IL (1) IL256248A (en)
MA (1) MA42270A (en)
MX (3) MX2018000261A (en)
MY (1) MY193727A (en)
NI (1) NI201700170A (en)
PE (1) PE20181090A1 (en)
PH (1) PH12017502311A1 (en)
RS (1) RS65347B1 (en)
SV (1) SV2017005607A (en)
UA (1) UA124799C2 (en)
WO (1) WO2016210223A1 (en)
ZA (1) ZA201800476B (en)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10201912554TA (en) * 2005-03-23 2020-02-27 Genmab As Antibodies against cd38 for treatment of multiple myeloma
SI2580243T1 (en) 2010-06-09 2020-02-28 Genmab A/S Antibodies against human cd38
US11053316B2 (en) 2013-01-14 2021-07-06 Xencor, Inc. Optimized antibody variable regions
CN110981964B (en) 2013-01-14 2023-09-15 Xencor股份有限公司 Novel heterodimeric proteins
US10858417B2 (en) 2013-03-15 2020-12-08 Xencor, Inc. Heterodimeric proteins
US9732154B2 (en) 2014-02-28 2017-08-15 Janssen Biotech, Inc. Anti-CD38 antibodies for treatment of acute lymphoblastic leukemia
US9603927B2 (en) 2014-02-28 2017-03-28 Janssen Biotech, Inc. Combination therapies with anti-CD38 antibodies
PL3122173T3 (en) 2014-03-26 2021-08-30 Scr Engineers Ltd Livestock location system
KR102497443B1 (en) 2014-03-28 2023-02-08 젠코어 인코포레이티드 Bispecific antibodies that bind to cd38 and cd3
US11071279B2 (en) 2014-09-05 2021-07-27 Intervet Inc. Method and system for tracking health in animal populations
US10986817B2 (en) 2014-09-05 2021-04-27 Intervet Inc. Method and system for tracking health in animal populations
WO2016040294A2 (en) 2014-09-09 2016-03-17 Janssen Biotech, Inc. Combination therapies with anti-cd38 antibodies
PE20171103A1 (en) 2014-11-26 2017-08-07 Xencor Inc HETERODIMERIC ANTIBODIES THAT BIND TO CD3 AND CD38
CA2967426A1 (en) 2014-11-26 2016-06-02 Xencor, Inc. Heterodimeric antibodies that bind cd3 and tumor antigens
US10259887B2 (en) 2014-11-26 2019-04-16 Xencor, Inc. Heterodimeric antibodies that bind CD3 and tumor antigens
SG11201704390PA (en) 2014-12-04 2017-06-29 Janssen Biotech Inc Anti-cd38 antibodies for treatment of acute myeloid leukemia
BR112017024877A2 (en) 2015-05-20 2019-09-17 Janssen Biotech, Inc. anti-cd38 antibody and its use in the treatment of light chain amyloidosis and other cd38 positive haematological malignancies
CA2990406A1 (en) 2015-06-22 2016-12-29 Janssen Biotech, Inc. Combination therapies for heme malignancies with anti-cd38 antibodies and survivin inhibitors
US20170044265A1 (en) 2015-06-24 2017-02-16 Janssen Biotech, Inc. Immune Modulation and Treatment of Solid Tumors with Antibodies that Specifically Bind CD38
BR112018008891A8 (en) 2015-11-03 2019-02-26 Janssen Biotech Inc antibodies that specifically bind to pd-1 and tim-3 and their uses
US10781261B2 (en) 2015-11-03 2020-09-22 Janssen Biotech, Inc. Subcutaneous formulations of anti-CD38 antibodies and their uses
EA202190808A2 (en) 2015-11-03 2021-12-31 Янссен Байотек, Инк. COMPOSITIONS OF ANTIBODIES TO CD38 FOR SUBCUTANEOUS ADMINISTRATION AND THEIR APPLICATION
CN108699136B (en) 2015-12-07 2022-03-18 Xencor股份有限公司 Heterodimeric antibodies that bind CD3 and PSMA
SG11201810023QA (en) 2016-05-27 2018-12-28 Agenus Inc Anti-tim-3 antibodies and methods of use thereof
RU2022104399A (en) 2016-06-14 2022-05-05 Ксенкор, Инк. BISPECIFIC ANTIBODIES-CHECKPOINT INHIBITORS
US11958913B2 (en) * 2017-01-09 2024-04-16 Biomunex Pharmaceuticals Polypeptide linker for preparing multispecific antibodies
JP2020505044A (en) * 2017-01-26 2020-02-20 サンガモ セラピューティクス， インコーポレイテッド B cell manipulation
CN111051344B (en) 2017-06-08 2023-10-27 黑带医疗有限公司 CD38 modulating antibodies
EP3434692A1 (en) * 2017-07-24 2019-01-30 Encefa Compounds which specifically binds to cd38 for use in the treatment of neurodegenerative diseases
US11542338B2 (en) 2017-08-16 2023-01-03 Black Belt Therapeutics Limited CD38 modulating antibody
MA50514A (en) 2017-10-31 2020-09-09 Janssen Biotech Inc HIGH-RISK MULTIPLE MYELOMA TREATMENT METHODS
AU2019256383A1 (en) 2018-04-17 2020-11-26 Celldex Therapeutics, Inc. Anti-CD27 and anti-PD-L1 antibodies and bispecific constructs
WO2019209712A1 (en) 2018-04-22 2019-10-31 Vence, Corp. Livestock management system and method
SG11202012993SA (en) * 2018-07-13 2021-02-25 Genmab As Variants of cd38 antibody and uses thereof
EP3820890A1 (en) * 2018-07-13 2021-05-19 Genmab A/S Trogocytosis-mediated therapy using cd38 antibodies
CN109265551B (en) * 2018-09-25 2020-09-15 华东师范大学 CD38 antibodies, chimeric antigen receptors, and drugs
CA3114173A1 (en) * 2018-09-27 2020-04-02 Musc Foundation For Research Development Pharmaceutical combination for the treatment of cancer
US11864529B2 (en) 2018-10-10 2024-01-09 S.C.R. (Engineers) Limited Livestock dry off method and device
WO2020194241A1 (en) * 2019-03-28 2020-10-01 Janssen Biotech, Inc. Clinically proven subcutaneous pharmaceutical compositions comprising anti-cd38 antibodies and their uses
JP2023510397A (en) 2020-01-16 2023-03-13 ジェンマブ エー／エス Formulations of CD38 antibodies and uses thereof
US11919956B2 (en) 2020-05-14 2024-03-05 Xencor, Inc. Heterodimeric antibodies that bind prostate specific membrane antigen (PSMA) and CD3
IL275518B (en) 2020-06-18 2021-10-31 Scr Eng Ltd An animal tag
USD990063S1 (en) 2020-06-18 2023-06-20 S.C.R. (Engineers) Limited Animal ear tag
USD990062S1 (en) 2020-06-18 2023-06-20 S.C.R. (Engineers) Limited Animal ear tag
KR102607909B1 (en) 2020-08-19 2023-12-01 젠코어 인코포레이티드 Anti-CD28 composition
WO2022113062A1 (en) 2020-11-25 2022-06-02 Scr Engineers Ltd. A system and method for tracing members of an animal population
WO2022117572A2 (en) 2020-12-02 2022-06-09 Oncurious Nv An ltbr agonist in combination therapy against cancer
AU2022208200A1 (en) 2021-01-14 2023-07-20 Morphosys Ag Anti-cd38 antibodies and their uses
TW202302642A (en) 2021-03-01 2023-01-16 德商莫菲西斯公司 Anti-cd38 antibodies for use in the treatment of antibody-mediated transplant rejection
CA3212665A1 (en) 2021-03-09 2022-09-15 Xencor, Inc. Heterodimeric antibodies that bind cd3 and cldn6
KR20230154311A (en) 2021-03-10 2023-11-07 젠코어 인코포레이티드 Heterodimeric antibodies binding to CD3 and GPC3
CN114805582B (en) * 2022-06-29 2022-10-04 上海恒润达生生物科技股份有限公司 anti-Trop 2 nano antibody and application thereof

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
ATE87659T1 (en) 1986-09-02 1993-04-15 Enzon Lab Inc BINDING MOLECULES WITH SINGLE POLYPEPTIDE CHAIN.
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US6172197B1 (en) 1991-07-10 2001-01-09 Medical Research Council Methods for producing members of specific binding pairs
US5932448A (en) 1991-11-29 1999-08-03 Protein Design Labs., Inc. Bispecific antibody heterodimers
ES2227512T3 (en) 1991-12-02 2005-04-01 Medical Research Council PRODUCTION OF ANTIBODIES AGAINST SELF-ANTIGENS FROM REPERTORIES OF ANTIBODY SEGMENTS FIXED IN A PHOTO.
CA2150262C (en) 1992-12-04 2008-07-08 Kaspar-Philipp Holliger Multivalent and multispecific binding proteins, their manufacture and use
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
AUPO591797A0 (en) 1997-03-27 1997-04-24 Commonwealth Scientific And Industrial Research Organisation High avidity polyvalent and polyspecific reagents
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
US7829693B2 (en) 1999-11-24 2010-11-09 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of a target gene
US6833441B2 (en) 2001-08-01 2004-12-21 Abmaxis, Inc. Compositions and methods for generating chimeric heteromultimers
EP1283053A1 (en) 2001-08-09 2003-02-12 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Inhibitors of HER3 activity
IL149820A0 (en) 2002-05-23 2002-11-10 Curetech Ltd Humanized immunomodulatory monoclonal antibodies for the treatment of neoplastic disease or immunodeficiency
CA2517145C (en) 2003-03-05 2017-08-01 Halozyme, Inc. Soluble hyaluronidase glycoprotein (shasegp), process for preparing the same, uses and pharmaceutical compositions comprising thereof
US8597911B2 (en) 2003-06-11 2013-12-03 Chugai Seiyaku Kabushiki Kaisha Process for producing antibodies
EP1720907B1 (en) 2004-02-06 2015-04-08 MorphoSys AG Anti-cd38 human antibodies and uses therefor
SG10201912554TA (en) * 2005-03-23 2020-02-27 Genmab As Antibodies against cd38 for treatment of multiple myeloma
WO2006106905A1 (en) 2005-03-31 2006-10-12 Chugai Seiyaku Kabushiki Kaisha Process for production of polypeptide by regulation of assembly
CA2970873C (en) 2005-05-09 2022-05-17 E. R. Squibb & Sons, L.L.C. Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics
EP1888647A2 (en) 2005-05-24 2008-02-20 MorphoSys AG Generation and profiling of fully human hucal gold®-derived therapeutic antibodies specific for human cd38
TWI428444B (en) 2005-10-12 2014-03-01 Morphosys Ag Generation and profiling of fully human hucal gold-derived therapeutic antibodies specific for human cd38
EP1999154B1 (en) 2006-03-24 2012-10-24 Merck Patent GmbH Engineered heterodimeric protein domains
JP2009541275A (en) 2006-06-22 2009-11-26 ノボ・ノルデイスク・エー／エス Production of bispecific antibodies
WO2008073160A2 (en) * 2006-08-17 2008-06-19 The Trustees Of Columbia University In The City Of New York Methods for converting or inducing protective immunity
SI2081595T1 (en) * 2006-09-26 2019-10-30 Genmab As Anti-cd38 plus corticosteroids plus a non-corticosteroid chemotherapeutic for treating tumors
EP1914242A1 (en) 2006-10-19 2008-04-23 Sanofi-Aventis Novel anti-CD38 antibodies for the treatment of cancer
US20080226635A1 (en) 2006-12-22 2008-09-18 Hans Koll Antibodies against insulin-like growth factor I receptor and uses thereof
WO2008119353A1 (en) 2007-03-29 2008-10-09 Genmab A/S Bispecific antibodies and methods for production thereof
EP3222634A1 (en) 2007-06-18 2017-09-27 Merck Sharp & Dohme B.V. Antibodies to human programmed death receptor pd-1
WO2009085462A1 (en) 2007-12-19 2009-07-09 Centocor, Inc. Design and generation of human de novo pix phage display libraries via fusion to pix or pvii, vectors, antibodies and methods
WO2009089004A1 (en) 2008-01-07 2009-07-16 Amgen Inc. Method for making antibody fc-heterodimeric molecules using electrostatic steering effects
CA2722466A1 (en) 2008-04-29 2009-11-05 Tariq Ghayur Dual variable domain immunoglobulins and uses thereof
AR072999A1 (en) 2008-08-11 2010-10-06 Medarex Inc HUMAN ANTIBODIES THAT JOIN GEN 3 OF LYMPHOCYTARY ACTIVATION (LAG-3) AND THE USES OF THESE
AU2009296392B2 (en) 2008-09-26 2016-06-02 Dana-Farber Cancer Institute, Inc. Human anti-PD-1, PD-L1, and PD-L2 antibodies and uses therefor
PE20120341A1 (en) 2008-12-09 2012-04-24 Genentech Inc ANTI-PD-L1 ANTIBODIES AND ITS USE TO IMPROVE T-CELL FUNCTION
JP2012525149A (en) 2009-04-27 2012-10-22 オンコメッド ファーマシューティカルズ インコーポレイテッド Method for making heteromultimeric molecules
KR101573109B1 (en) 2009-11-24 2015-12-01 메디뮨 리미티드 Targeted binding agents against b7-h1
SG184427A1 (en) 2010-04-20 2012-11-29 Genmab As Heterodimeric antibody fc-containing proteins and methods for production thereof
WO2011143545A1 (en) 2010-05-14 2011-11-17 Rinat Neuroscience Corporation Heterodimeric proteins and methods for producing and purifying them
SI2580243T1 (en) * 2010-06-09 2020-02-28 Genmab A/S Antibodies against human cd38
EP2420253A1 (en) 2010-08-20 2012-02-22 Leadartis, S.L. Engineering multifunctional and multivalent molecules with collagen XV trimerization domain
JP6167040B2 (en) 2010-11-05 2017-07-19 ザイムワークス，インコーポレイテッド Design of stable heterodimeric antibodies with mutations in the Fc domain
JOP20210044A1 (en) * 2010-12-30 2017-06-16 Takeda Pharmaceuticals Co Anti-cd38 antibodies
CA2833636A1 (en) 2011-04-20 2012-10-26 Amplimmune, Inc. Antibodies and other molecules that bind b7-h1 and pd-1
US9856320B2 (en) * 2012-05-15 2018-01-02 Bristol-Myers Squibb Company Cancer immunotherapy by disrupting PD-1/PD-L1 signaling
WO2014017966A1 (en) 2012-07-24 2014-01-30 Telefonaktiebolaget L M Ericsson (Publ) Apparatus and method for dynamically selecting a random access response window value for use with random access procedures in a network
US9682143B2 (en) * 2012-08-14 2017-06-20 Ibc Pharmaceuticals, Inc. Combination therapy for inducing immune response to disease
DK2914302T3 (en) * 2012-11-05 2017-04-10 Morphosys Ag RADIOACTIVALLY MARKED ANTIBODY AND USES OF IT
EA033115B1 (en) 2013-04-29 2019-08-30 Тева Фармасьютикалз Острэйлиа Пти Лтд. Anti-cd38 antibodies and fusion proteins with attenuated interferon alpha-2b
US20140356318A1 (en) * 2013-05-28 2014-12-04 Israel Barken Adoptive cell therapy with specific regulatory lymphocytes
JP6563906B2 (en) 2013-05-31 2019-08-21 ソレント・セラピューティクス・インコーポレイテッドＳｏｒｒｅｎｔｏ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． Antigen binding protein that binds to PD-1
AU2014290186A1 (en) * 2013-07-15 2016-02-04 The Board Of Trustees Of The Leland Stanford Junior University Medical uses of CD38 agonists
JP2016536361A (en) * 2013-11-06 2016-11-24 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Pharmaceutical formulation comprising CD33 antibody and demethylating agent
US9603927B2 (en) * 2014-02-28 2017-03-28 Janssen Biotech, Inc. Combination therapies with anti-CD38 antibodies

Also Published As

Publication number Publication date
UA124799C2 (en) 2021-11-24
CA2990620A1 (en) 2016-12-29
GT201700286A (en) 2019-08-08
MY193727A (en) 2022-10-27
AU2016281717B2 (en) 2022-07-28
CN107921120A (en) 2018-04-17
EP3313441A4 (en) 2019-04-24
PH12017502311A1 (en) 2018-06-25
JP2018527299A (en) 2018-09-20
EP3313441A1 (en) 2018-05-02
WO2016210223A1 (en) 2016-12-29
EA037548B1 (en) 2021-04-12
US20160376373A1 (en) 2016-12-29
CO2017013332A2 (en) 2018-05-21
HK1254942A1 (en) 2019-08-02
EP3313441B1 (en) 2024-02-21
CL2017003275A1 (en) 2018-04-20
KR20180012864A (en) 2018-02-06
AU2016281717A1 (en) 2018-01-18
RS65347B1 (en) 2024-04-30
MX2021012133A (en) 2021-11-03
CL2019003657A1 (en) 2020-05-08
PE20181090A1 (en) 2018-07-09
ECSP17084878A (en) 2018-02-28
DK3313441T3 (en) 2024-04-15
JP2022070892A (en) 2022-05-13
DOP2017000305A (en) 2018-04-15
JP7041519B2 (en) 2022-03-24
EA201890131A1 (en) 2018-05-31
ZA201800476B (en) 2021-05-26
NI201700170A (en) 2019-05-10
MX2021012134A (en) 2021-11-03
SV2017005607A (en) 2019-03-28
BR112017027990A2 (en) 2018-08-28
FI3313441T3 (en) 2024-03-28
MX2018000261A (en) 2018-03-08
IL256248A (en) 2018-02-28

Similar Documents

Publication Publication Date Title
MA42270A (en) IMMUNE MODULATION AND SOLID TUMOR TREATMENT WITH ANTIBODIES BINDING SPECIFICALLY TO CD38
HK1259075A1 (en) Bcma antibodies and use of same to treat cancer and immunological disorders
MA43305A (en) HETERODIMERIC ANTIBODIES BINDING TO CD3 AND CD38 ANTIGENS
IL267113A (en) Antibodies that specifically bind to human il-15 and uses thereof
MA41279A (en) HETERODIMERIC ANTIBODIES BINDING TO CD3 AND TUMOR ANTIGENS
MX2021003704A (en) Heterodimeric antibodies that bind cd3 and tumor antigens.
EA201891083A1 (en) COMPOSITIONS OF ANTIBODIES TO CD38 FOR SCRAPTURE AND THEIR APPLICATION
MA55629A (en) ANTIBODY COMPOSITIONS FOR THE TREATMENT OF TUMORS
EA201791485A1 (en) ANTI-CD47-ANTIBODIES AND THEIR APPLICATIONS
EA201691582A1 (en) NEW PHARMACEUTICAL PREPARATIONS
MA40682B1 (en) Anti-ox40 antibodies and methods of use thereof
EA201691610A8 (en) ANTI-JAGGED1 ANTIBODIES AND METHODS OF APPLICATION
MA44072A (en) ANTIBODIES SPECIFICALLY BINDING TO HLA-DR AND THEIR USES
IL264962A (en) Anti-vegf-a and anti-ang2 antibodies and uses thereof
PH12018500659A1 (en) Compounds effective in treating hepatotoxicity and fatty liver diseases and uses thereof
MA46086A (en) DOSAGE SCHEDULE FOR THE TREATMENT OF SOLID TUMORS
IL251676A0 (en) Antibodies that bind to ccr6 and their uses
GB201618424D0 (en) Treatment of antibody mediated disease
IL255314A0 (en) Anti-ap2 antibodies and antigen binding agents to treat metabolic disorders
FR3039166B1 (en) CD34 + CD41DIM MEGACARYOCYTE PROGENITORS AND USES THEREOF TO PRODUCE PLAQUETTES AND / OR MK CARRIING PROPLAQUETS
MA39355A1 (en) Anti-ox40 antibodies and methods of use thereof
EA202092495A1 (en) Cot MODULATORS AND METHODS OF THEIR APPLICATION
GB201516437D0 (en) Compositions and methods relating to the treatment of disease
CN302517191S (en) Harmful Substance Extractor
TH1501005488A (en) Agents that induce apoptosis for Treatment of cancer as well as immune and autoimmune diseases